Get access

Newer anticonvulsants: Lamotrigine, topiramate and gabapentin

Authors

  • Lewis B. Holmes,

    Corresponding author
    1. Genetics Unit, MassGeneral Hospital for Children, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
    2. North American Antiepileptic Drug Pregnancy Registry, Massachusetts General Hospital, Somerville, Massachusetts
    • Genetics Unit, MassGeneral Hospital for Children, 175 Cambridge Street, 504, Boston, MA 02114
    Search for more papers by this author
  • Sonia Hernandez-Diaz Dr.PH

    1. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
    2. North American Antiepileptic Drug Pregnancy Registry, Massachusetts General Hospital, Somerville, Massachusetts
    Search for more papers by this author

Abstract

BACKGROUND The second generation antiepileptic drugs (AEDs), which include lamotrigine, topiramate, and gabapentin, have been introduced during the past 20 years. Because the newer AEDs differ in their pharmacokinetics from the first generation AEDs, it is hoped that the second generation AEDs will be less teratogenic. METHODS The findings in pregnancy cohorts and case-control studies concerning lamotrigine, topiramate and gabapentin-exposed pregnancies have been analyzed. RESULTS The rate of all malformations in lamotrigine monotherapy-exposed pregnancies has been between 2.0 and 5.6%, in comparison to baseline rates of 1.1 to 3.6% in two unexposed comparison groups. Compared to reference populations, a higher risk (0.4%) of isolated oral clefts has been observed in one cohort of 1562 lamotrigine-exposed pregnancies, but the risk was lower (0.1%) in other studies. In topiramate-exposed pregnancies, the rate of all malformations has been 4.2 to 4.9%, with an increase in oral clefts with and without other anomalies. The limited information available now for gabapentin has shown no evidence of teratogenicity. Concerning other developmental effects of these drugs, young children exposed to lamotrigine in utero have shown no deficits in cognitive function. Prenatal exposure to topiramate has been associated with an elevated frequency of small size for gestational age newborns. CONCLUSIONS The information available suggests an increased risk of oral clefts in infants exposed to topiramate, and perhaps lamotrigine, early in pregnancy, and of growth retardation for topiramate-exposed infants. Larger sample sizes are needed to clarify the questions that have been raised. Birth Defects Research (Part A) 94:599–606, 2012. © 2012 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary